Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 ...
Q1 2026
May 13, 2026
FY 2025
Mar 24, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 5, 2025